Bekinda: Completed Ph III GUARD enrollment

RedHill completed enrollment of 320 patients in the double-blind, placebo-controlled, U.S. Phase III GUARD trial of 24 mg oral Bekinda (see BioCentury, Oct. 26, 2015)....